205 related articles for article (PubMed ID: 29137875)
1. Contribution of
Gómez-de la Fuente FJ; Martínez-Rodríguez I; de Arcocha-Torres M; Quirce R; Jiménez-Bonilla J; Martínez-Amador N; Banzo I
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(3):156-162. PubMed ID: 29137875
[TBL] [Abstract][Full Text] [Related]
2. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of
López Rodríguez E; Tirado Hospital JL; Álvarez Pérez RM; Gómez Izquierdo L; Jiménez-Hoyuela JM
Actas Urol Esp (Engl Ed); 2020; 44(6):437-443. PubMed ID: 32576406
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility and therapeutic impact of PET/CT [
Sánchez N; Valduvieco I; Ribal MJ; Campos F; Casas F; Nicolau C; Salvador R; Mellado B; Jorcano S; Fuster D; Paredes P
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):284-291. PubMed ID: 32467000
[TBL] [Abstract][Full Text] [Related]
5. Value of
García JR; Compte A; Buxeda M; Mourelo S; Soler M; Blanch A; Valls E; Riera E
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):197-203. PubMed ID: 32165153
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of
Martínez-Rodríguez I; de Arcocha-Torres M; Gómez-de la Fuente FJ; Jiménez-Bonilla J; Sánchez-Salmón A; Martínez-Amador N; Mendi-Barcina V; Andrés-Pacheco J; Gutiérrez-González A; Pombo-López M; Bota-Bota A; Rodil-Gallego M; García-Ruiz A; Quirce R
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(2):93-99. PubMed ID: 36427802
[TBL] [Abstract][Full Text] [Related]
8. Role of PET-CT with
Puche-Sanz I; Triviño-Ibáñez E; Vázquez-Alonso F; Llamas-Elvira JM; Cózar-Olmo JM; Rodríguez-Fernández A
Actas Urol Esp; 2017 Sep; 41(7):437-444. PubMed ID: 28389027
[TBL] [Abstract][Full Text] [Related]
9. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.
Ceci F; Castellucci P; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Ntreta M; Lodi F; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):878-86. PubMed ID: 24346416
[TBL] [Abstract][Full Text] [Related]
10. The role of positron emission tomography/computed tomography imaging with radiolabeled choline analogues in prostate cancer.
Navarro-Pelayo Láinez MM; Rodríguez-Fernández A; Gómez-Río M; Vázquez-Alonso F; Cózar-Olmo JM; Llamas-Elvira JM
Actas Urol Esp; 2014 Nov; 38(9):613-21. PubMed ID: 24548475
[TBL] [Abstract][Full Text] [Related]
11. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
[TBL] [Abstract][Full Text] [Related]
12.
Michaud L; Touijer KA; Mauguen A; Zelefsky MJ; Morris MJ; Lyashschenko SK; Durack JC; Humm JL; Weber WA; Schöder H
J Nucl Med; 2020 Jun; 61(6):827-833. PubMed ID: 31862801
[TBL] [Abstract][Full Text] [Related]
13. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
[TBL] [Abstract][Full Text] [Related]
14.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
15. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
[TBL] [Abstract][Full Text] [Related]
16. Mediastinal lymph node uptake in patients with prostate carcinoma on F18-choline PET/CT.
Rietbergen DD; van der Hiel B; Vogel W; Stokkel MP
Nucl Med Commun; 2011 Dec; 32(12):1143-7. PubMed ID: 22045476
[TBL] [Abstract][Full Text] [Related]
17. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
Barbaud M; Frindel M; Ferrer L; Le Thiec M; Rusu D; Rauscher A; Maucherat B; Baumgartner P; Fleury V; Colombié M; Thierry-Morel A; Kraeber-Bodéré F; Campion L; Rousseau C
Prostate; 2019 Apr; 79(5):454-461. PubMed ID: 30549066
[TBL] [Abstract][Full Text] [Related]
18.
Garg I; Nathan MA; Packard AT; Kwon ED; Larson NB; Lowe V; Davis BJ; Haloi R; Mahon ML; Goenka AH
J Cancer Res Ther; 2021; 17(2):358-365. PubMed ID: 33063697
[TBL] [Abstract][Full Text] [Related]
19. Correlation between molecular tumor volume evaluated with
Medina-Ornelas Sevastián S; García-Pérez Francisco O; Hernández-Pedro Norma Y; Arellano-Zarate Angélica E; Abúndiz-López Blanca L
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(4):223-228. PubMed ID: 29454548
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]